CurrentCignaPolicy IP0083

Human Immunodeficiency Virus - Rukobia

Defines Cigna coverage and prior authorization criteria for Rukobia (fostemsavir) as combination therapy in heavily treatment-experienced adults with multidrug-resistant HIV-1, and who may continue therapy if responding.

Policy Summary

PayerCigna

PolicyHuman Immunodeficiency Virus - Rukobia

Policy CodePolicy IP0083

Change TypeCoverage criteria revisedauthorization durations updated

Effective Date

Next Review Date

Key ActionObtain prior authorization with documentation that the adult patient is failing current ARV therapy, has exhausted ≥4 ARV classes, and will use Rukobia with an optimized background regimen.

SourceLink

POLICY UPDATE CHANGES

Initial therapy approval duration updated from 12 months to 6 months.

Initial eligibility revised from 'History of multi-drug resistant HIV' to 'According to the prescriber, the patient is failing a current antiretroviral regimen for HIV.'

Added explicit criterion that the patient has exhausted at least four antiretroviral classes (defined as elimination of all antiretrovirals within a given class due to resistance or significant intolerance).

Reauthorization (current Rukobia users) clarified to approve for 1 year if continued combination therapy and prescriber-determined response documented.

Policy title updated from 'Fostemsavir' to 'Human Immunodeficiency Virus - Rukobia' and indication wording updated to 'Human Immunodeficiency Virus-1 Infection.'

6 monthsInitial approval duration

1 yearReauthorization duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ARV classes required

Adults ≥18Age requirement

BRIGHTE n=371Pivotal study size

Coverage Criteria for Rukobia (fostemsavir)

FDA-Approved Indication

Covered when ONE of the following is met

Overall indication: Patient meets either Initial Therapy (A) OR Currently Receiving Rukobia (B)

A) Initial Therapy: Approve for 6 months if ALL of the following are met

A.i Age: Patient is ≥ 18 years of age

chunk 8

A.ii Regimen failure: According to the prescriber, the patient is failing a current antiretroviral regimen for HIV

chunk 8

A.iii Class exhaustion: According to the prescriber, the patient has exhausted at least FOUR of the following antiretroviral classes defined as elimination of all antiretrovirals within a given class due to demonstrated or projected resistance to the agent(s) in that class OR due to significant intolerance: a) Nucleoside reverse transcriptase inhibitors (examples: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, tenofovir alafenamide, zidovudine); b) Non-nucleoside reverse transcriptase inhibitors (examples: delavirdine, efavirenz, etravirine, nevirapine, nevirapine XR, rilpivirine); c) Protease inhibitors (examples: atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir); d) Fusion inhibitors (example: enfuvirtide [Fuzeon] subcutaneous injection); e) Integrase strand transfer inhibitors (examples: dolutegravir, elvitegravir, raltegravir); f) CCR5 antagonists (example: maraviroc [Selzentry])>= 4 classes exhausted

chunks 8,9

A.iv Combination therapy: Medication will be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents

chunk 9

A.v Specialist involvement: Prescribed by or in consultation with a physician who specializes in the treatment of HIV infection

chunk 9

B) Patient is Currently Receiving Rukobia: Approve for 1 year if BOTH of the following are met

B.i Continued combination therapy: Medication will continue to be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents

chunk 9

B.ii Clinical response documented: Patient has responded to a Rukobia-containing regimen, as determined by the prescriber (examples: HIV-1 RNA < 40 copies/mL, ≥0.5 log10 reduction from baseline in viral load, or improvement or stabilization of CD4 T-cell count)

chunk 9

Rukobia (fostemsavir) for any use not described in the FDA‑approved indication and the specific coverage criteria in this policy is considered not medically necessary. Criteria will be updated as new published data become available.

Use of Rukobia for indications other than the FDA‑approved treatment of Human Immunodeficiency Virus‑1 (HIV‑1) infection as specified in this policy is considered not medically necessary.

Coding and Clinical Measures

Neutral — drug identifier informationmixed

Rukobia (fostemsavir) NDC/Coding

Policy references prescribing information but does not list specific billing codes or NDCs in document.

Virologic response examples — thresholds

Primary virologic suppression exampleHIV-1 RNA < 40 copies/mL

Relative virologic response example≥ 0.5 log10 reduction from baseline in HIV-1 RNA

Study evidence for suppression thresholdBRIGHTE pivotal trial reported 54% of patients achieved HIV‑1 RNA < 40 copies/mL at Week 48 (Rukobia + optimized background therapy)

CD4 T‑cell monitoring — responses and thresholds

Critical CD4 thresholdCD4 T-cell count < 200 cells/mm3 associated with higher risk; improvements to ≥ 200 cells/mm3 observed in treated patients

Monitoring frequency guidanceCD4 count recommended at entry into care, when switching/modifying ARVs, then every 3, 6, or 12 months depending on CD4 and duration of viral suppression

Provider Actions, Prior Authorization, and Reauthorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for Rukobia. Initial approvals are provided for 6 months and Rukobia must be prescribed by or in consultation with a physician who specializes in the treatment of HIV infection. For patients currently receiving Rukobia, reauthorization may be approved for 1 year if the patient continues combination therapy and the prescriber documents patient response (examples: HIV‑1 RNA < 40 copies/mL, ≥ 0.5 log10 reduction from baseline, or improvement/stabilization of CD4 T‑cell count). Receipt of sample product does not satisfy criteria requirements for coverage.

Initial approval: 6 months; prescriber must be an HIV specialist or in consultation with one.
Reauthorization for current Rukobia users: up to 1 year with documented response and ongoing combination therapy.

Denial Risk

Claims Coding and Criteria Noncompliance

Claims submitted without covered diagnosis or procedure codes, or not in accordance with the policy criteria, will be denied as not covered. When billing, providers must use the most appropriate codes as of the date of submission. Reimbursement is not allowed for services billed for conditions or diagnoses that are not covered under this Coverage Policy.

Background

Rukobia for any other use is considered not medically necessary. The policy will be revised when new published evidence supports additional indications.

Definitions

Exhaustion — definition and required classes

Definition of class exhaustionElimination of all antiretrovirals within a given class as a fully active option due to demonstrated or projected resistance, previous adverse events, or significant intolerance

Number of classes requiredAt least four antiretroviral classes must be exhausted for initial approval

Classes listed as examplesNucleoside reverse transcriptase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Fusion inhibitors; Integrase strand-transfer inhibitors; CCR5 antagonists

Optimized background regimen — requirement and context

Optimized background regimen requirementRukobia must be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents

Constructing regimen per study design

Policy Summary

PayerCigna

PolicyHuman Immunodeficiency Virus - Rukobia

Policy CodePolicy IP0083

Change TypeCoverage criteria revisedauthorization durations updated

Effective Date

Next Review Date

SourceLink

On This Page

Clinical response example involving CD4Improvement or stabilization of CD4 T-cell count may be used by prescriber to document response for reauthorization

Claims lacking covered codes will be denied as not covered.
Use the most appropriate and current diagnosis/procedure codes when billing.

Step Therapy

Clinical Positioning vs Step Therapy

This policy aligns with clinical guidance recommending use of novel agents (e.g., Rukobia) for heavily treatment‑experienced patients with multidrug‑resistant HIV-1 who are failing current regimens and lack sufficient treatment options. It does not impose explicit step therapy; rather, use is positioned for patients meeting guideline-based criteria (e.g., exhausted antiretroviral classes and need for an optimized background regimen).

Policy is consistent with DHHS and international/consensus guidelines recommending novel agents for heavily treatment‑experienced patients.
Not an explicit step‑therapy requirement; intended for patients who have exhausted multiple ARV classes and require optimized background regimens.

Documentation Required

Required Documentation for Prior Authorization

Prescribers must document patient-specific information to support prior authorization, including age, evidence the patient is failing current antiretroviral regimen, documentation that at least four antiretroviral classes have been exhausted due to resistance or intolerance, that Rukobia will be used in combination with an optimized background regimen, and that the prescriber is an HIV specialist or consulted one. For reauthorization, prescribers must document continued use with combination therapy and clinical response as noted above.

Document age (≥ 18 years for initial therapy).
Document failure of current ARV regimen and exhaustion of ≥ 4 ARV classes (resistance or intolerance).
Document optimized antiviral background regimen including one or more other ARVs.
For reauthorization, document clinical response (e.g., HIV‑1 RNA < 40 copies/mL, ≥ 0.5 log10 reduction, or CD4 improvement/stabilization).
Prescriber is an HIV specialist or consulted one; note consultation.
Receipt of samples does not meet criteria.

Optimized background regimens in BRIGHTE were based on number of fully active available ARVs (randomized cohort: 1–2 fully active ARVs; non-randomized cohort: none)

Clinical guidanceGuidelines recommend novel-mechanism agents like Rukobia ideally be combined with two fully active ARVs when possible in individuals with extensive multiclass resistance